Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
Roche announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder…
Read More...
Read More...